(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

EPITOX

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

EPITOX

ST13

US500000079287183

Class

5

Filing

79287183

Registration

6405698

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

32

Latest update

07/06/2026

Trademark type

Combined

Nice classes

5

Filing date

04/23/2020

Registration date

07/06/2021

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

07/06/2021

Last transaction

07/06/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

5

Owner type

99

Owner location

KR

Examiner

LEE, JANET H

Law office

N60

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

JETEMA CO., LTD.

Representatives

Benjamin M. Cantor Cantor Colburn LLP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations for treating middle of the forehead wrinklesfacial wrinklesasymmetries and defects and conditions of the human skin; pharmaceutical preparations for treating orthopaedic purposes; pharmaceutical preparations acting on the central nervous system; analgesic preparations; medicines for dental purposes; therapeutic drugs and agents as pharmaceuticals for treatment of wrinkles; pharmaceutical preparations for treating pain; pharmaceutical products for skin care for medical purposesbotulinum toxinbotulinum toxin-hemagglutinin complexbotulinum toxin fragments and other derivatives; pharmaceutical preparations for treating neurological diseasesbotulinum toxinbotulinum toxin-hemagglutinin complexbotulinum toxin fragments and other derivatives; pharmaceutical preparation for skin care; medicated skin preparation for use in treating wrinkles; pharmaceutical preparations for treatment of respiratory organ disorder; preparations for the treatment of burns; preparations for the treatment of scar; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for treating muscle disorders; pharmaceutical agents affecting metabolism; bacterial poisons; anaesthetics; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for treating middle of the forehead wrinkles; pharmaceutical preparations for use in the cosmetic fieldmedicated cosmetics; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; botulinum toxin for medical use for use in the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; pharmaceutical preparations for the treatment of urogenital organ disorders; pharmaceutical preparations for plastic surgery; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; veterinary substances and preparations for house pets for injuries and painpharmaceuticals containing botulinum toxin; cardiovascular agents for medical purposes; pharmaceutical preparations for treating neurological disorders; ophthalmic preparations; pharmaceutical preparations for treating facial cramps; allergy medications; chemical preparations for pharmaceutical purposesfor neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; chemico-pharmaceutical preparationsfor neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; pharmaceutical preparations for treating facial wrinkles; pharmaceutical agents for epidermis; drugs for medical purposespharmaceutical preparations for the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; medicines for human purposespharmaceutical preparations for the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain

Publications

History of USPTO decisions and trademark events.

32 publications found

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

07/06/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

10/06/2023

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

11/28/2021

FICS

FINAL DISPOSITION NOTICE SENT TO IB

11/04/2021

FIMP

FINAL DISPOSITION PROCESSED

11/04/2021

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/06/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

07/06/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/20/2021

PUBO

PUBLISHED FOR OPPOSITION

04/20/2021

GPNX

NOTIFICATION PROCESSED BY IB

04/18/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

03/31/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

03/31/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/31/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/18/2021

XAEC

EXAMINER'S AMENDMENT ENTERED

03/18/2021

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

03/18/2021

GNEA

EXAMINERS AMENDMENT E-MAILED

03/18/2021

CNEA

EXAMINERS AMENDMENT -WRITTEN

03/18/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/25/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/24/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/24/2021

NREP

NEW REPRESENTATIVE AT IB RECEIVED

02/05/2021

NREP

NEW REPRESENTATIVE AT IB RECEIVED

01/02/2021

RFNT

REFUSAL PROCESSED BY IB

09/27/2020

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

09/05/2020

RFRR

REFUSAL PROCESSED BY MPU

08/24/2020

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

07/17/2020

CNRT

NON-FINAL ACTION WRITTEN

07/16/2020

DOCK

ASSIGNED TO EXAMINER

07/15/2020

MAFR

APPLICATION FILING RECEIPT MAILED

06/16/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

06/12/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

06/11/2020

Continuous trademark protection

Get notified about every new filing that threatens EPITOX or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.